Agreements

Date: 2017-05-18

Type of information: Research agreement

Compound: Paraxial Mesoderm Multipotent Cells (P2MCs) technology

Company: Anagenesis Biotechnologies (France) Boehringer Ingelheim (Germany)

Therapeutic area: Muscle disorders

Type agreement: R&D -research

Action mechanism:

cell therapy. The P2MC technology allows for the efficient, reproducible and chemically defined differentiation of pluripotent cells into muscle fibers and adult muscle stem cells, also known as satellite cells. This technology was developed with the support of AFM-telethon, INSERM Transfert, CNRS and Strasbourg University.

Disease: chronic muscle diseases

Details:

• On May 18, 2017, Anagenesis Biotechnologies announced a strategic research agreement with Boehringer Ingelheim, which grants Boehringer Ingelheim an exclusive access to Anagenesis’ proprietary Paraxial Mesoderm Multipotent Cells (P2MCs) technology for chronic muscle diseases. The agreement will support the Boehringer Ingelheim R&D efforts in the discovery of treatments for chronic musculoskeletal diseases such as sarcopenia and cachexia. A High Throughput Screening assay developed by Anagenesis using wild type human muscle progenitors enriched in satellite cells will be used to identify small molecules inducing myogenesis. Boehringer Ingelheim is the third partnership for Anagenesis in the past 18 months, and follows agreements with Ksilink in Duchenne muscular disease and CRISPR Therapeutics in cell therapy for muscle diseases.

Financial terms:

Latest news: